Interpretation 2169
Tier 1|
|
|
Primary Sites
Tumor Types
Interpretation
Dasatinib Nilotinib
Citations
- von Mehren M Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors. Clin Colorectal Cancer 2006;6 Suppl 1():S30-4
- Reichardt P, et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol 2012;23(7):1680-7
- Sawaki A, et al. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer 2011;117(20):4633-41
- Montemurro M, et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer 2009;45(13):2293-7
Last updated: 2018-04-06 15:15:55 UTC